drugset / Trial / NCT04731909
Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluates the effectiveness and safety of Toripalimab combined with Anlotinib and chemotherapy for the first-line treatment of ES-SCLC, and maintenance therapy are Toripalimab combined with Anlotinib.
Timeline
- Start
- 2018-10-01
- Primary completion
- 2022-06-01
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |